Abstract
Objectives: To systematically review evidence on the cost-effectiveness of abemaciclib in the treatment of HR+/HER2− advanced or metastatic breast cancer.
Research methods: A systematic review was conducted in accordance with PRISMA 2020. PubMed, Cochrane, and Embase were searched up to March 1, 2026. Eligible studies were assessed using the CHEERS checklist. Cost data were converted to Vietnamese dong (VND) at 2025 values.
Results: Eight studies were included, conducted in the Americas and Asia, mainly from the payer or healthcare system perspective. Compared with endocrine therapy alone, abemaciclib was cost-effective in 4 of 7 relevant studies. When compared with other CDK4/6 inhibitors, the findings were less consistent. The ICER was mainly influenced by drug costs, utility values, and clinical effectiveness parameters.
Conclusion: The cost-effectiveness of abemaciclib was inconsistent across studies and depended on the comparator, treatment line, drug price, and reimbursement context. Further research in Vietnam is needed to support reimbursement decisions and price negotiation.
Keywords
abemaciclib; cost-effectiveness; breast cancer; HR+/HER2−; systematic review.
References
[1]
1. (IARC). IAfRoC. Global Cancer Observatory: Cancer Today – Population fact sheets 2022 [Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf.
Google Scholar
[2]
2. Mao Y, Chu X, Xie F, Fu L, Ding Z, Zhang W, et al. Estimates and projections of the global economic cost of breast cancers from 2021 to 2050. Front Endocrinol (Lausanne). 2025;16:1692619. doi: 10.3389/fendo.2025.1692619
Google Scholar
[3]
3. Saatci O, Huynh-Dam KT, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med (Berl). 2021;99(12):1691-710. doi: 10.1007/s00109-021-02136-5
Google Scholar
[4]
4. Sledge GW, Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-84. doi: 10.1200/jco.2017.73.7585
Google Scholar
[5]
5. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-46. doi: 10.1200/jco.2017.75.6155
Google Scholar
[6]
6. Grischke EM, Llombart-Cussac A, Toi M, Neven P, Sohn J, Inoue K, et al. Final overall survival analysis of MONARCH 2: a Phase 3 trial of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative Advanced Breast Cancer. Oncology research and treatment. 2023;46:30. doi: 10.1159/000533576
Google Scholar
[7]
7. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71. doi: 10.1136/bmj.n71
Google Scholar
[8]
8. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. 2022 [3-9]. Available from: https://www.equator-network.org/reporting-guidelines/cheers/.
Google Scholar
[9]
9. Campbell and Cochrane Economics Methods Group (CCEMG). CCEMG–EPPI Centre Cost Converter 2024 [Available from: https://eppi.ioe.ac.uk/costconversion/.
Google Scholar
[10]
10. Tổng cục thống kê. Báo cáo tình hình kinh tế - xã hội quý IV và năm 2025 2025 [Available from: https://www.nso.gov.vn/bai-top/2026/01/bao-cao-tinh-hinh-kinh-te-xa-hoi-quy-iv-va-nam-2025/.
Google Scholar
[11]
11. Elazzazy S, Al-Ziftawi NH, Mohamed Ibrahim MI, Bujassoum S, Hamad A. Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation. Frontiers in Oncology. 2024;14. doi: 10.3389/fonc.2024.1413676
Google Scholar
[12]
12. Molina-Jaimes M, Galindo-González A, Verduzco-Aguirre HC, Bautista-Arredondo S, Reyes-Terán G, Soto-Perez-de-Celis E. Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2- breast cancer in Mexico. Clin Transl Oncol. 2024;26(1):239-44. doi: 10.1007/s12094-023-03247-w
Google Scholar
[13]
13. Schroeder Damico Nascimento Macedo L, Silveira Silva A, Wekmuller França AC, Alberto da Silva Magliano C, Meirelles I, Piccin Padilla M, et al. Cost-Utility of the CDK 4/6 Inhibitors for Postmenopausal Women With Luminal Advanced Breast Cancer in Brazil. Value in Health Regional Issues. 2022;31:47-52. doi: 10.1016/j.vhri.2022.02.006
Google Scholar
[14]
14. Lin X, Lan Y, Wang J, Zhao W, Liu X, Huang Z. Cost-effectiveness analysis of Anastrozole combined with Abemaciclib for the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Cost Effectiveness and Resource Allocation. 2025;23(1). doi: 10.1186/s12962-025-00605-z
Google Scholar
[15]
15. Sun L, Veenstra DL, Brufsky A, Pluard T, Sandin R, Stergiopoulos S, et al. First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eligible population. Journal of Managed Care and Specialty Pharmacy. 2025;31(10):1039-50. doi: 10.18553/jmcp.2025.25063
Google Scholar
[16]
16. Xie Q, Zheng H, Li Q. Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. Breast Care. 2022;17(3):237-43. doi: 10.1159/000518551
Google Scholar
[17]
17. Wang Y, Rui M, Guan X, Cao Y, Chen P. Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective. Front Med (Lausanne). 2021;8:658747. doi: 10.3389/fmed.2021.658747
Google Scholar
[18]
18. Wang K, Liu S, Li S, Gao J. Cost-effectiveness analysis of CDK4/6 inhibitors in the second-line treatment for HR+/HER2- advanced or metastatic breast cancer. Front Pharmacol. 2025;16:1540088. doi: 10.3389/fphar.2025.1540088
Google Scholar